This weekend I'll be attending the Biomedical Optics Symposium (BiOS), which now represents 45% of the educational content at Photonics West. Saturday night will find me at the appropriately named Hot Topics plenary, which promises to deliver "the latest technical breakthroughs and directions from leading worldwide experts.” Each year, this plenary showcases some of the most interesting work underway—mostly in research, but also in the commercial realm.
This weekend I'll be attending the Biomedical Optics Symposium (BiOS), which now represents 45% of the educational content at Photonics West. Saturday night will find me at the appropriately named Hot Topics plenary, which promises to deliver "the latest technical breakthroughs and directions from leading worldwide experts.” Each year, this plenary showcases some of the most interesting work underway—mostly in research, but also in the commercial realm.
This year’s Hot Topics will begin with a tribute to Michael Feld, the MIT professor who pioneered the application of spectroscopy to biomedicine. Not long after BiOS 2010, Feld lost his battle with cancer, but his presence is still with us, as will be demonstrated in a discussion of recent work that promises to overcome obstacles to the long-anticipated promise of noninvasive glucose monitoring and tomographic cell imaging.
Showing posts with label near infrared spectroscopy. Show all posts
Showing posts with label near infrared spectroscopy. Show all posts
Tuesday, January 18, 2011
Wednesday, June 3, 2009
Urodynamix's financial report indicates demand for NIRS technology
This week, Urodynamix Technologies Ltd. reported exciting news: Financial results for its fiscal first quarter (ended March 31) showed a 1,269%increase from revenues in Q1 2008. The spike resulted from the first commercial sales of the company's URO NIRS 2000 in the quarter--and as of March 31, the company had an order backlog of $92,576.
This week, Urodynamix Technologies Ltd. reported exciting news: Financial results for its fiscal first quarter (ended March 31) showed a 1,269% increase from revenues in Q1 2008. The spike resulted from the first commercial sales of the company's URO NIRS 2000 in the quarter--and as of March 31, the company had an order backlog of $92,576.
Urodynamix has been busy working partnerships to get its near infrared spectroscopy products out into the world. For instance a new agreement with pharmaceuticals giant Pfizer has the partners collaborating on promotional programs to increase awareness of UroNIRS Bladder Monitor technology among urologists and medical professionals. And a product development and distribution agreement with Timm Medical Technologies aims to apply NIRS to erectile dysfunction.
This week, Urodynamix Technologies Ltd. reported exciting news: Financial results for its fiscal first quarter (ended March 31) showed a 1,269% increase from revenues in Q1 2008. The spike resulted from the first commercial sales of the company's URO NIRS 2000 in the quarter--and as of March 31, the company had an order backlog of $92,576.
Urodynamix has been busy working partnerships to get its near infrared spectroscopy products out into the world. For instance a new agreement with pharmaceuticals giant Pfizer has the partners collaborating on promotional programs to increase awareness of UroNIRS Bladder Monitor technology among urologists and medical professionals. And a product development and distribution agreement with Timm Medical Technologies aims to apply NIRS to erectile dysfunction.
Subscribe to:
Posts (Atom)